Clinical Trial Update: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update discusses a Phase 2 study of SHAPE in IA, IB or IIA Cutaneous T-Cell Lymphoma assessing efficacy, safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• SHAPE

Snippet

Sponsor: TetraLogic Pharmaceuticals | Conditions: Cutaneous T-Cell Lymphoma (CTCL) | Phase 2 | Status: UNKNOWN